ArticleComparative medicine2011
Development of a mouse model for assessing fatigue during chemotherapy.
Article in Comparative medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Chronotherapeutic administration of neoadjuvant chemotherapy reduces cancer-related fatigue-like behavior.Brain, behavior, & immunity - health · 2026Article
- Early oral administration of THC:CBD formulations prevent pain-related behaviors without exacerbating paclitaxel-induced changes in weight, locomotion, and anxiety in a rat model of chemotherapy-induced neuropathy.Psychopharmacology · 2025Article
- Article
- Comprehensive review of mouse models for studying cancer-related fatigue: Methods, findings and future directions (Review).Experimental and therapeutic medicine · 2025Review
- Effects of mammary cancer and chemotherapy on neuroimmunological markers and memory function in a preclinical mouse model.Brain, behavior, & immunity - health · 2023Article
- Microglia are implicated in the development of paclitaxel chemotherapy-associated cognitive impairment in female mice.Brain, behavior, and immunity · 2023Article
- Deleterious and protective effects of epothilone-D alone and in the context of amyloid β- and tau-induced alterations.Frontiers in molecular neuroscience · 2023Article
- Antibiotic treatment inhibits paclitaxel chemotherapy-induced activity deficits in female mice.PloS one · 2023Article
- Induction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker.Cancers · 2022Article
- Exercise protocols: The gap between preclinical and clinical exercise oncology studies.Metabolism open · 2022Article
- Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression.Frontiers in pharmacology · 2022Article
- Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice.Brain, behavior, and immunity · 2022Article
- Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice.Journal of cachexia, sarcopenia and muscle · 2021Article
- Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy.Brain, behavior, and immunity · 2021Article
- Voluntary wheel running ameliorates select paclitaxel chemotherapy-induced sickness behaviors and associated melanocortin signaling.Behavioural brain research · 2021Article
- The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice.Frontiers in oncology · 2020Article
- Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice.Scientific reports · 2019Article
- Myeloid-Derived Lymphatic Endothelial Cell Progenitors Significantly Contribute to Lymphatic Metastasis in Clinical Breast Cancer.The American journal of pathology · 2019Article
- A novel mutation in Slc2a4 as a mouse model of fatigue.Genes, brain, and behavior · 2019Article
- Mammary tumors compromise time-of-day differences in hypothalamic gene expression and circadian behavior and physiology in mice.Brain, behavior, and immunity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Fatigue and disturbed sleep are common problems for cancer patients and affect both quality of life and compliance with treatment. Fatigue may be associated with cancer itself and with the treatment, particularly for therapies with neurotoxic side effects. To develop a model system for evaluation of chemotherapy-related fatigue, we studied mice treated with either a commonly used formulation of the chemotherapeutic agent paclitaxel (paclitaxel; Taxol), which is known to have neurotoxic properties, or a nano- particle formulation of paclitaxel (nab-paclitaxel; Abraxane) that is reported to have greater potency and efficacy yet fewer side effects than does paclitaxel. Mice were treated with 1 of these 2 agents (10 mg/kg IV daily for 5 consecutive days) and were monitored from 1 wk before through 4 wk after treatment. Dependent measures included running wheel activity, locomotor activity on the cage floor, core temperature, sleep patterns, CBC count, serum cytokine and chemokine concentrations, and neurologic assessment. For both drugs, mice showed the most severe perturbations of activity during the first recovery week after drug administration. Mice treated with paclitaxel showed greater neutropenia and motor deficits than did mice treated with nab-paclitaxel. However, deficits had largely resolved by 4 wk after administration of either drug. We conclude that these measures provide an assessment of chemotherapy-related fatigue that potentially can distinguish toxicity associated with different formulations of the same agent.
Indexed as
Identifiers
21535922PMC3079813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.